Clinical trials: TB Infection
Lung Tuberculosis, MDR TB
Tuberculosis Research of INA-RESPOND On Drug Resistance
This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray…
- Trial name
- TRIPOD (NCT02758236)
- Testing
- No Intervention
- Where
- 7 sites in Indonesia
- Volunteers
- 490 people
- Sponsor
- Ina-Respond
Latent Tuberculosis, HIV
Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa
The purpose of this study is to use a cluster randomized trial to compare the effectiveness of linking the Quantiferon-gold in-tube test (QGIT) with routine CD4 testing to the routine use of the tuberculin skin test (TST), the…
- Trial name
- NCT02119130
- Testing
- QGIT
- Where
- 14 sites in South Africa
- Volunteers
- 3,506 people
- Sponsor
- Johns Hopkins University
Tuberculosis, Pulmonary, Antibiotic Prophylaxis
Prevention of Tuberculosis in Prisons
The purpose of this study is to determine if the isoniazid is effective in the prevention of tuberculosis in a prison population, exposed to the high endemicity of the disease.
- Trial name
- NCT03028129
- Testing
- Isoniazid 900 milligrams
- Where
- Brazil
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Federal University of Mato Grosso
Lung Diseases, Tuberculosis
Indigenous Outreach Among Injection Drug Users to Treat and Control TB
The Community Outreach Intervention Project (COIP) implemented and evaluated a TB intervention with injection drug users (IDUs) in two Chicago Neighborhoods, guided by the indigenous outreach leadership model that had been used…
- Trial name
- NCT00005741
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Tuberculosis
Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis
The purpose of this study is: To evaluate the safety and tolerability of orally administered OPC-67683 when administered two times daily to MDR tuberculosis (TB) participants refractory to treatment with an optimized background…
- Trial name
- NCT01131351
- Testing
- Delamanid, Optimized Background Regimen (OBR)
- Where
- 3 sites in Latvia, Lithuania
- Volunteers
- 10 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis
Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients
Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 10 causes of mortality worldwide. It is estimated that in 2017, 10 million people were infected with TB, and 1.6 million died from the disease…
- Trial name
- NCT06709157
- Testing
- P24 antigens and antibody, zeihl - Nelsen stain, culture on Lowenstein jensen media
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
Tuberculosis
The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa
The purpose of this study is to compare two different methods of intensified tuberculosis (TB) case finding in the community. These methods all involve the use of a mobile clinic to reach people with TB symptoms who are not able…
- Trial name
- XACT (NCT01990274)
- Testing
- GeneXpert MTB/RIF assay, Smear microscopy
- Where
- 4 sites in Italy, Netherlands and 2 more
- Volunteers
- 875 people
- Sponsor
- University of Cape Town
HIV I Infection, Tuberculosis
Evaluating the Safety and Immunogenicity of MTBVAC
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
- Trial name
- HVTN605A5421 (NCT05947890)
- Testing
- MTBVAC, BCG
- Where
- 16 sites in South Africa
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Tuberculosis
Role of EBUS-TBNA in Diagnosing TB in Mediastinal/Hilar Lymph Nodes
This is an observational prospective study. Role of EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration) is evaluated to diagnose tuberculosis in mediastinal and/or hilar lymph nodes.
- Trial name
- NCT01350674
- Testing
- EBUS-TBNA
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Tuberculosis
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects
This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a longitudinal study of pulmonary TB suspects who are undergoing sputum evaluation for pulmonary TB.
- Trial name
- NCT01587469
- Where
- United States
- Volunteers
- 992 people
- Sponsor
- Cepheid
HIV
HIV-Tb Confections Among HIV Patients
A cross sectional study would be done for prevalence of HIV-Tb. co infection among patients of HIV enrolled at ART centre, Khagaria, India, during June' 2015 to May' 2016.
- Trial name
- NCT02964767
- Where
- India
- Volunteers
- 219 people
- Sponsor
- Singh, Ranjan Kumar, M.D.
Tuberculosis, Pulmonary
Azacytidine During Anti-tuberculosis Therapy
Tuberculosis has been shown to make immune genes inaccessible and slows immune response The purpose of this research is to see if if azacitidine is safe and can return the ability of the body to resist tuberculosis (TB), a…
- Trial name
- AZA (NCT03941496)
- Testing
- Azacitidine Injection
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Andrew Dinardo
Human Immunodeficiency Virus (HIV) Infection
Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis
SaDAPT is a pragmatic, randomized, therapeutic-use trial comparing two approaches ("ART first" versus "TB results first") for the timing of ART initiation in PLHIV with presumptive TB, but no signs of central nervous system (CNS)…
- Trial name
- SaDAPT (NCT05452616)
- Testing
- ART first- Therapeutic use trial, TB results first- Therapeutic use trial
- Where
- 2 sites in Lesotho, Malawi
- Volunteers
- 610 people
- Sponsor
- University Hospital, Basel, Switzerland
HIV Infections, Tuberculosis
TB-LAM in the Diagnosis of TB
Tuberculosis (TB) is still the leading cause of death in HIV-infected patients. Early diagnosis of TB substantially improves the survival of HIV-infected patients.
- Conditions
- HIV Infections, Tuberculosis, Non-Tuberculous Mycobacterial Pneumonia
- Trial name
- NCT04600232
- Testing
- Alere TB-LAM
- Volunteers
- 400 people
- Sponsor
- Shanghai Public Health Clinical Center
Tuberculosis, Spinal, Tuberculosis, Osteoarticular
Gene Expression Profiles in Spinal Tuberculosis.
Tuberculosis (TB) is one of the top ten causes of death worldwide with approximately 10 million cases globally and 1.2 million deaths. Sub-Saharan Africa carries the highest burden of TB.
- Conditions
- Tuberculosis, Spinal, Tuberculosis, Osteoarticular, Tuberculosis, Mycobacterium Infections
- Trial name
- SpinalTBX (NCT05610098)
- Where
- South Africa
- Volunteers
- 100 people
- Sponsor
- University of Cape Town
Inflammatory Rheumatic Diseases
A Study on Changes in IFN-gamma Levels Following Anti-TNF Treatment in Patients Undergoing Serial QuantiFERON-TB Gold In-Tube
The screening for latent tuberculosis infection (LTBI) prior to the onset of anti-tumor necrosis factor therapy, as well as a watchful monitoring during the treatment, is strongly recommended.
- Trial name
- NCT01475409
- Testing
- QuantiFERON-TB Gold In-Tube (QFT-GIT)
- Volunteers
- 119 people
- Sponsor
- University of Roma La Sapienza
Tuberculosis
Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine
The study is a single centre, phase I, double-blind, randomized, placebo-controlled trial that explored the safety and immunogenicity of 2 doses (Day 1 and Day 21) TB/FLU-04L tuberculosis vaccine versus matched placebo in…
- Trial name
- NCT02501421
- Testing
- tuberculosis vaccine
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems
Tuberculosis
Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers
The purpose of this study is to evaluate the experimental tuberculosis (TB) vaccine called ID93+GLA-SE. The safety, immunogenicity, and efficacy of ID93+GLA-SE will be compared to placebo, after three intramuscular (IM)…
- Trial name
- NCT03806686
- Testing
- ID93+GLA-SE
- Where
- 3 sites in South Korea
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
Tuberculosis
Self-verification and Support Via Mobile Phones Drastically Improves Tuberculosis Treatment Success in LMIC Settings
Each year, 10.4 million patients are diagnosed with and 1.8 million people die from Tuberculosis (TB). Despite the availability of highly effective and accessible medications in the developing world where TB is endemic, the 6-18…
- Trial name
- NCT03135366
- Testing
- Keheala, Standard of Care
- Volunteers
- 1,190 people
- Sponsor
- Yale University
Ageing, Tuberculosis
Performance of IGRAs for TB Infection Diagnosis in Elderly
Background: Diagnosis and screening for latent tuberculosis in old patients is of special interest in regards of the morbidity-mortality of this disease in that context.
- Trial name
- IGRage (NCT01895582)
- Testing
- Blood samples
- Where
- 3 sites in France
- Volunteers
- 160 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris